Publications by authors named "Mutlu Demiray"

Claim this Profile

Mentions over time

Mentions by platform

Video Views

1,626,662

Total Likes

16,617

Extended Reach

2,356,148

Social Features

104
E
Exceptional Response to MEK Inhibition in a Patient With RAF1-Mutant Myxofibrosarcoma: Case Report and Mechanistic Overview.
Eylül Özgü, Esranur Aydin, Ashkan Adibi, Ünal Metin Tokat, Onur Tutar, Jiancheng Hu, Irem Demiray, Razelle Kurzrock, Mutlu Demiray

JCO Precis Oncol· September 2023

Videos about Article: user user user 3

6 2 98 2

View All Article and Social Media Activity
E
Exceptional Response in a Patient with mRCC Through Precision-Guided Treatment Involving Immunotherapy Rechallenge with Temsirolimus and Bevacizumab.
Ashkan Adibi, Ünal Metin Tokat, Esranur Aydın, Eylül Özgü, Şevval Nur Bilgiç, Mutlu Demiray

J Immunother Precis Oncol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Erratum: Precision-Guided Durable Response From Venetoclax With Decitabine in a Patient With a Metastatic Refractory -Mutant Cholangiocarcinoma.
Eylül Özgü, Ünal Metin Tokat, Ashkan Adibi, Şevval Nur Bilgiç, Esranur Aydın, Mutlu Demiray

JCO Precis Oncol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Precision-Guided Durable Response From Venetoclax With Decitabine in a Patient With a Metastatic Refractory -Mutant Cholangiocarcinoma.
Eylül Özgü, Ünal Metin Tokat, Ashkan Adibi, Şevval Nur Bilgiç, Esranur Aydın, Mutlu Demiray

JCO Precis Oncol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Case report: Near-complete response to neratinib-based treatment in HR-positive -amplified metastatic breast cancer refractory to trastuzumab deruxtecan.
Ünal Metin Tokat, Ashkan Adibi, Esranur Aydın, Şevval Nur Bilgiç, Eylül Özgü, Mutlu Demiray

Front Oncol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Elacestrant plus alpelisib in an and co-mutated and heavily pretreated metastatic breast cancer: the first case report for combination efficacy and safety.
Ünal Metin Tokat, Şevval Nur Bilgiç, Esranur Aydın, Ashkan Adibi, Eylül Özgü, Mutlu Demiray

Ther Adv Med Oncol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Therapeutic vulnerabilities and pan-cancer landscape of BRAF class III mutations in epithelial solid tumors.
Eylül Özgü, Benjamin G Kaplan, Smruthy Sivakumar, Ethan S Sokol, Esranur Aydın, Mutlu Demiray

BJC Rep· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Personalized Immunotherapy Achieves Complete Response in Metastatic Adenoid Cystic Carcinoma Despite Lack of Conventional Biomarkers.
Ünal Metin Tokat, Ashkan Adibi, Esranur Aydın, Eylül Özgü, Şevval Nur Bilgiç, İrem Demiray, Mutlu Demiray

Curr Oncol· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The value of virtual molecular tumor boards for informed clinical decision-making.
Martín Angel, Mutlu Demiray, Umut Dişel, João Passos

Oncologist· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Durable radiologic and molecular complete response following nivolumab in an HNSCC patient with UV signature and HIV.
Ashkan Adibi, Ünal Metin Tokat, Eylül Özgü, Nurseit Mamyrov, Esranur Aydın, Mutlu Demiray

Oral Oncol· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Case report: Precision guided reactive cancer management: molecular complete response in heavily pretreated metastatic CRC by dual immunotherapy and sorafenib.
Esranur Aydın, Ünal Metin Tokat, Ashkan Adibi, Eylül Özgü, Şevval Nur Bilgiç, Mutlu Demiray

Front Oncol· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Navigating uncharted territory: a case report and literature review on the remarkable response to personalized crizotinib containing combinational therapy in a pazopanib refractory patient with novel alterations.
Esranur Aydın, Ünal Metin Tokat, Eylül Özgü, Ashkan Adibi, Onur Tutar, Mutlu Demiray

Ther Adv Med Oncol· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PARP inhibitor combinations with high-dose vitamin C in the treatment of Ewing sarcoma: two case reports and mechanistic overview.
Ashkan Adibi, Ünal Metin Tokat, Eylül Özgü, Esranur Aydın, İrem Demiray, Mutlu Demiray

Ther Adv Med Oncol· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Levan enhanced the NF-κB suppression activity of an oral nano PLGA-curcumin formulation in breast cancer treatment.
Zahra Eskandari, Fatemeh Bahadori, Vildan Betul Yenigun, Mutlu Demiray, Mehmet Sayip Eroğlu

Int J Biol Macromol· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combinatorial Therapy of High Dose Vitamin C and PARP Inhibitors in DNA Repair Deficiency: A Series of 8 Patients.
Mutlu Demiray

Integr Cancer Ther· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Realistic View on "The Essential Medicinal Chemistry of Curcumin".
Fatemeh Bahadori, Mutlu Demiray

ACS Med Chem Lett· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A cross-sectional survey of the diagnosis and management of bone metastasis in breast cancer patients in Turkey.
Ali Arican, Tulin Bozkurt, Hakan Bozcuk, Binnaz Demirkan, Suleyman Buyukberber, Mutlu Demiray

Support Care Cancer· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Response to neoadjuvant chemotherapy in breast cancer could be predictable by measuring a novel serum apoptosis product, caspase-cleaved cytokeratin 18: a prospective pilot study.
Mutlu Demiray, Engin Engin Ulukaya, Murat Arslan, Sehsuvar Gokgoz, Ozlem Saraydaroglu

Cancer Invest· November 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
5
5-Fluorouracil, epirubicin and cisplatin in the treatment of metastatic gastric carcinoma: a retrospective analysis of 68 patients.
Kanat Ozkan, Evrensel Turkkan, Kurt Ender, Demiray Mutlu, Arslan Murat

Indian J Cancer· October 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II study of gemcitabine plus paclitaxel in metastatic breast cancer patients with prior anthracycline exposure.
Mutlu Demiray, Ender Kurt, Turkkan Evrensel, Ozkan Kanat, Murat Arslan

Cancer Invest· October 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of clinical outcomes of different erythropoietin usage strategies.
Murat Arslan, Turkkan Evrensel, Ender Kurt, Mutlu Demiray, Guzin Gonullu

Tumori· November 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of the effects of Helicobacter pylori eradication therapy on gastric antral epithelial hyperproliferation: a prospective six-month follow-up study.
Mutlu Demiray, Macit Gulten, Osman Manavoglu, Turkkan Evrensel, Engin Ulukaya, Hulya Demiray

Hepatogastroenterology· October 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic value of nm23 in gastrointestinal stromal tumors.
Ozkan Kanat, Saduman Adim, Turkkan Evrensel, Omer Yerci, Bulent Ediz, Mutlu Demiray

Med Oncol· July 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment of metastatic pancreatic cancer with a combination of gemcitabine and 5-fluorouracil: a single center phase II study.
Ozkan Kanat, Turkkan Evrensel, Ender Kurt, Mutlu Demiray, Guzin Gonullu

Tumori· July 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Acquired lymphangiectasis after breast conservation treatment for breast cancer: report of a case.
Ismet Tasdelen, Sehsuvar Gokgoz, Ela Paksoy, Omer Yerci, Sibel Kahraman Cetintas, Mutlu Demiray

Dermatol Online J· July 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis